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Poster Session I S267Results: Disease status (relapse/refractory, CR2, or CR3) did not
have a significant effect on disease-free survival (p 5 0.75). Clonal
evolution, however, did have a significant negative impact on dis-
ease-free survival (p 5 0.03). Day 100 disease free survival was
50% versus 100% for patients with and without clonal evolution, re-
spectively. Similarly, one year disease-free survival was 20% and
83% for patients with and without clonal evolution. Among the pa-
tients with clonal evolution, there was no significant difference in
disease-free survival between patients with only one new cytogenetic
abnormality and those with more than one new cytogenetic abnor-
mality (p 5 0.19).
Conclusion: Clonal evolution appears to identify a very high-risk
group of patients who may benefit from novel transplant strategies
and post-HSCT interventions. Future studies should seek to validate
these findings in a multi-institutional setting.310
HYPERTENSION IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANT PATIENTS
Owens, C.1, Ashraf, K.1, Chong, D.1, Stesco, N.1, Depuis, L.1,
Fernandez, C.2, Gassas, A.1, Nathan, P.1, Doyle, J.1, Schechter-
Finkelstein, T.1 1Hospital for Sick Children, Toronto, ON, Canada;
2 IWK Health Center, Halifax, NS, Canada
Allogeneic haematopoietic stem cell transplant (AlloHSCT) in
children is associated with serious complications. Hypertension
(HT) is reported to occur in 21-63% of adult HSCT patients.
Data on the incidence of HT in children undergoing HSCT are lim-
ited.
Objectives: To establish the incidence of and identify the risk fac-
tors associated with the development of HT in pediatric AlloHSCT
patients and to determine the duration and impact of HT on cardiac
function at one year and overall survival (OS).
Methods: We conducted a retrospective study of all children who
underwent AlloHSCT at The Hospital for Sick Children from
2004 to 2007 and were followed in Toronto or Halifax. Demo-
graphic information, underlying diagnosis, conditioning regimen,
GvHD prophylaxis, blood pressure, GvHD, survival, medication
history and echocardiography results were collected in the first
year post HSCT.
Results: 172 children (59% male; mean age 5 8.46 years; range
0.25-18 years) underwent AlloHSCT during the study period.
67% had an underlying malignant disease; 83% received myeloabla-
tive conditioning and 45% received total body irradiation. 93% re-
ceived cyclosporine for GVHD prophylaxis, most commonly in
combination with methotrexate (78%). Stem cell donors were: living
related donor (LRD) in 51%; living unrelated donor (LURD) in
33% and unrelated cord in 16%.
111/172 (65%) developed HT in the first 100 days after Al-
loHSCT.Childrenwithmalignant disease were less likely to develop
HT compared to children without a malignancy (p\ 0.008). Chil-
dren who had a non-cord HSCT and developed GVHD were
more likely to develop HT (p 5 0.045). Gender, age and condition-
ing regimen were not associated with HT. 36/149 (24%) evaluable
children were hypertensive at D+90, 16/138 (12%) at D+180 and
5/126 (4%) at one year. No child had ventricular dysfunction (mea-
sured by echo) at one year. A total of 46 patients had died by one year
post transplant. HT did not influence OS at one year after Al-
loHSCT (p 5 0.37).
Conclusions:HToccurs commonly post AlloHSCT in children but
usually resolves by one year post transplant. HT did not lead to car-
diac impairment or influence OS at one year.311
SIGNATURE PROFILES OF CMV-SPECIFIC T-CELLS IN PEDIATRIC PA-
TIENTS WITH CMV REACTIVATION AFTER HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Krol, L.1,2, Stuchly, J.2, Hubacek, P.1, Sedlacek, P.1, Kalina, T.1,2
1Charles University 2nd Faculty of Medicine and University Hospital Mo-
tol, Prague, Czech Republic; 2Charles University 2nd Faculty of Medicine
and University Hospital Motol, Prague, Czech RepublicDepletion of cellular immunity as a consequence of condition-
ing before allogeneic hematopoietic stem cell transplantation fre-
quently results in CMV reactivation, which may in turn lead to
life-threatening infections and require timely antiviral treatment.
We have investigated the functional signatures of CMV-specific
CD4+ and CD8+ T-cells in 191 samples from 118 individuals.
We included patients with either high or undetectable viral loads,
and those who controlled or did not control their CMV reactiva-
tions. All patient subsets were compared to healthy donors. Poly-
chromatic flow cytometric measurements of CD154 (CD40L),
intracellular cytokines (IFNg, IL2), and a degranulation marker
(CD107a) revealed the functional status of various T-cells simul-
taneously. We found that dual IFNg/IL2 producing CD8+
T-cells were significantly decreased in patients non-controlling
their CMV reactivations compared to controllers. In contrast,
CD8+ T-cells that produced IFNg only were the most abundant
subtype but they were present in a substantial number of non-
controllers. Hierarchical clustering of distinct functional signa-
tures revealed that polyfunctional CD8+ T-cells were acting in
concert with other subsets, whereas the isolated production of
IFNg by CD8+ T cells heralds insufficient collaboration with
others. In conclusion, our study revealed functional signatures
that may be useful for immune monitoring, and they may change
the interpretation of previous studies that assessed only IFNg.
Supported by the Czech Ministry of Health grant NS/9996-4 and
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MOLECULAR DETECTION OF ADENOVIRUS IN PEDIATRIC HEMATOPOI-
ETIC STEM CELL TRANSPLANT RECIPIENTS
Watson, T.M.1, MacDonald, D.2, Song, X.3,2, Bromfield, K.1,
Stevenson, A.1, Campos, J.M.2,3, Sande, J.1,3, DeBiasi, R.L.3,2 1Child-
ren’s National Medical Center, Washington, DC; 2Children’s National
Medical Center,Washington, DC; 3GeorgeWashingtonUniversity School
of Medicine, Washington, DC
Background: Adenoviral (AdV) infections are a major cause of mor-
bidity and mortality in hematopoietic stem cell transplant (HSCT)
patients (pts). Quantitative molecular detection of AdV using poly-
merase chain reaction (PCR) has recently becomemore widely avail-
able in the clinical setting for early detection and monitoring of AdV
infection, although challenges regarding interpretation of results and
implications for treatment remain.
Methods:Weperformed a retrospective cohort study of all pediatric
HSCT pts who underwent AdV PCR testing from May 2008
through April 2010. Clinical characteristics of AdV-positive (POS)
pts were compared to AdV-negative (NEG) pts.
Results: Of 48 pts with AdV testing, 43 had complete transplant
records and were included in the analysis. Seven (16.3%) pts were
AdV-POS. Overall pt characteristics were comparable between
the two groups. The following medication exposures were identi-
fied as risk factors influencing AdV status: preparatory regimens
utilizing fludarabine (Relative Risk [RR] 8.73, 95% Confidence
Interval [CI]: 1.18-64.27, p 0.006), melphelan (RR 3.47, 95%
CI 0.76-15.94, p 0.08), and/or cyclophosphamide (RR 0.18,
95% CI 0.02-1.4, p 0.05), and GVHD prophylaxis with methyl-
prednisone (RR 3.73, 95% CI 1.01-13.9, p 0.04). AdV-POS pts
had higher GVHD grades with higher rates of GVHD of the gas-
trointestinal tract (RR 4, 95% CI 1.18-13.5, p 0.03) compared to
AdV-NEG pts. Amongst seven AdV-POS pts, 57.1% had con-
comitant clinical manifestations of disease including: pneumonia,
diarrhea, and/or disseminated disease. Clinical outcomes in four
symptomatic pts included resolution of disease (2) and death (2),
although one pt had concomitant bacterial sepsis. An additional
AdV–POS pt had prolonged marrow suppression as a probable
clinical manifestation of AdV disease and recovered. All AdV-
POS pts received antiviral therapy, including one pt with severe
disseminated disease that resolved following administration of li-
posomal cidofovir.
Conclusion:Our study at a large pediatric HSCT transplant cen-
ter confirms previously identified risk factors for AdV infection in
previous small studies in adults and children. This study provides
important preliminary data for the design of a prospective trial
which aims to identify specific HCST patient populations who
S268 Poster Session Imight benefit most from molecular screening and early pre-
emptive therapy.313
THE SUCCESS OF AUTOLOGOUS TRANSPLANT FOR PEDIATRIC RE-
LAPSED/REFRACTORY HODGKIN LYMPHOMA IS MOST INFLUENCED BY
THE DISEASE STATUS PRE-TRANSPLANT
Margossian, S.P.,Williams, T., Billett, A.L., Duncan, C., Lehmann, L.E.
Dana Farber/Children’s Hospital Cancer Center, Boston, MA
Background: Autologous peripheral blood stem cell transplant
(aPBSCT) is a standard treatment approach for patients with re-
lapsed or refractory Hodgkin Lymphoma (HL). The current liter-
ature suggests the 3 year event free survival for HL patients
following aPBSCT ranges from 40-65% with 5% events due
to transplant related mortality and recurrent disease accounting
for the rest.
Methods:We conducted a retrospective analysis of all pediatric pa-
tients who were transplanted for HL at the DF/CHCC from 1/1/00
to 12/31/09. 24 patients with refractory (n5 9) or relapsed (n5 15)
HL underwent aPBSCT, including 2 patients with multiple relapses
and one with initial refractory disease who subsequently progressed
prior to aPBSCT (scored as refractory). Any patient whose disease
progressed during first therapy was considered refractory, even if
there was an initial disease response.
Patients:There were 13 males and 11 females analyzed, average age
14 yrs (8 yr-20.5 yr). Disease stage at presentation ranged from IIa to
IVb. Histology included NS (n 5 20), mixed cellularity (n 5 3) and
LP (n5 1). Disease progression/recurrence was confirmed by biopsy
in 22 of 24 patients. Salvage regimens varied, with ICE (n5 12) and
venorelbine regimens (n 5 9) most common.
Results: 22/24 patients came to transplant in CR (defined as
negative functional study and . 50% tumor response by CT);
1/24 in VGPR (defined as negative functional study and\ 50%
CT response) and 1/24 with active disease on PET with 50% re-
sponse by CT. All patients were conditioned with BEAM
(carmustine/etoposide/cytarabine/melphalan) followed by reinfu-
sion of cryopreserved autologous cells. There was 1 toxic death
at day +12 (4%) in a patient previously intubated for Stevens-
Johnson syndrome, and 1 relapse (4%) occurring 6 months after
aPBSCT.
Conclusion: aPBSCT is a proven modality to salvage patients with
HL who fail frontline therapy. In our series, conditioning with
BEAM followed by aPBSCT had a TRM (4 %) consistent with
that reported for autologous transplant. Disease progression was
seen in only one patient. Notably this was the only patient with func-
tional evidence of active disease at time of transplant. 92% (22/24) of
patients who presented for aPBSCT are alive and well with a median
follow-up of 60 months. Length of first CR, stage of disease or num-
ber of relapses prior to transplant did not seem to impact survival.
These results suggest achieving excellent EFS is most influenced
by disease control pre-aPBSCT.314
PROCALCITONIN IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANT (AHSCT) RECIPIENTS
Watson, T.M.1, Fry, T.J.2, Jacobsohn, D.A.1, Sande, J.1,3, Yates, B.1,
Stevenson, A.1 1Children’s National Medical Center, Washington, DC;
2Center for Cancer Research, NCI, NIH, Bethesda, MD; 3George Wash-
ington University School of Medicine, Washington, DC
The mortality of aHSCT remains unacceptably high and is of-
ten related to inflammation from infection and/or graft-versus-
host disease (GVHD). Identifying markers of inflammation may
allow tailoring of therapy in high-risk patients (pts). Studies
show PCT as a useful marker in assessing the severity of bacterial
infections. We conducted a prospective pilot study measuring
serial procalcitonin (PCT) and other inflammatory markers in pe-
diatric aHSCT pts. The goal of this ongoing study is to identify
biomarkers that would be predictive of infection and other post-
transplant complications.
Pts were enrolled prior to preparative regimen, and serum was
collected pre-transplant, day of stem cell infusion (D0), biweeklyuntil engraftment, and on day 30, 60, and 100. Samples were
run using Time Resolved Amplified Cryptate Emission technol-
ogy.
Thirteen pts have been enrolled, with a median age of 10 (1-21)
years and the following diagnoses: AML (4), ALL (2), bone marrow
failure (4), thalassemia (2), and sickle cell disease (1). Stem cell
sources include HLA matched related donor (4), matched unrelated
donor (8), and sibling cord (1). The conditioning regimen was abla-
tive in 7 and reduced intensity in 6.
To date, we have pre-transplant and D0 data on all pts. Median
PCT values showed significant differences at the 2 time points
(pre-transplant 0.105 ng/dl [0.000-0.350] vs D0 0.315 ng/dl
[0.035-7.230], p 0.02] with no effect from conditioning regimen.
Of pts with blood culture positive sepsis (2), neither had PCT .
2.0 ng/dl. Pts with GVHD (6) did not have an elevation in PCT.
One pt requiring intensive care for acute renal failure and develop-
ment of respiratory failure due to parainfluenza had significantly el-
evated PCT (peak 20 ng/dl).
This data suggest that an elevation in PCT on D0 is associated
with inflammation caused by preparative regimens. Although the
exact mechanism of PCT is unknown, it is hypothesized that
PCT synthesis is induced by TNF-a or IL-6, which are known
to play a role in preparative regimen-induced inflammation. We
are currently measuring GM-CSF, IFN-g, IL-1b, IL-2, IL-6,
IL-8, IL-10, IL-12p70, and TNF-a by multiplex assay to corre-
late with PCT levels and clinical outcomes. We hypothesize
that PCT will be lower on DO after reduced intensity regimens
given less inflammation and toxicity. More subjects need to be
enrolled to determine whether D0 levels are predictive of toxicity
and whether post-transplant PCT can predict GVHD and/or
infection.315
PHERIPHERAL BLOOD STEM CELL COLLECTION IN AUTOLOGOUS STEM
CELL TRANSPLANTATION, EXPERIENCE IN A SINGLE PEDIATRIC CENTER
IN COLOMBIA
Chaparro, M., Estupi~nan, M. Hospital de la Misericordia, Bogota, DC,
Colombia
Between August 2007 and December 2009 all patients with ma-
lignancies those that were candidates to autologous stem cell
transplantation had been included. All patients were mobilized
by chemotherapy and G-CSF 5 mgr/kg/day, leukapheresis was
performed when the leukocytes were . 1,000/l. All patients had
a long time catheter Hickman-Broviac or high flow hemodyalisis
catheter through a jugular or subclavian vein, inserted by pediatric
surgery team. All procedures were performed by the continuous
flow blood cell separator Amicus- Fenwal by using manufacturer
provided mononuclear cell computer software. The extracorpo-
real volume of the device is 163 ml and the extracorporeal eryth-
rocyte volume is 79 ml during the mononuclear collection phase.
Between all available devices in Colombia Amicus has the lower
extracorporeal volume. Amicus device has been tested in adults
and children. To avoid cardiovascular effects some children with
low hemoglobin level received irradiated packed RBC without
priming the system as described previously in children with
a weigh lower than 15kg.
A total of 16 procedures were performed in 12 patients, 8 females,
and 4 males. Diagnoses were: neuroblastoma n5 8 lymphoma n5 3
(Hodgkin Lymphoma 2, Large B Cell lymphoma 1), Ewing’s Sar-
coma n5 1. Themedian age was 7 years (2- 17 years) and themedian
weigh 23,5 Kg (12- 50 Kg). The median collection time was 281,2
min. (163- 391 min.), the blood volume processed was 8568,6 ml
(range 1349- 5566 ml), blood volume was processed in a median of
2,5 times (range 2,5- 7 times), all procedures were large-volume leu-
kapheresis. Median weight of product was 107 gr. (Range 45- 155
gr.)The median number of PBPC collected was 4,8 mononuclear
cells (MNC)108/kg (range 0,2–21) and 8,41 CD34+ cells106/kg
(range 0.08– 54).
No circulatory side effects were observed during the procedures.
No one patient required sedation and the only symptoms observed
were associated to hypocalcaemia (muscle spasms of hands in tree pa-
tient weighs 14, 15 y 17Kg). In those patients median blood volume
processed was 6,3 times.
